低剂量与传统剂量TMP-SMX治疗非HIV肺孢子菌肺炎的多中心回顾性队列研究
该多中心回顾性队列研究纳入非HIV肺孢子菌肺炎(PCP)患者,比较低剂量(TMP<12.5 mg/kg/d)与传统剂量(TMP 12.5-20 mg/kg/d)TMP-SMX的疗效与安全性。经倾向评分重叠加权调整后,两组30天和180天死亡率无显著差异,但低剂量组不良事件(尤其恶心和低钠血症)发生率显著更低。
要点
- 低剂量TMP-SMX与传统剂量相比,非HIV PCP患者30天和180天死亡率无显著差异。
核心结论
- 低剂量与传统剂量TMP-SMX治疗非HIV PCP的生存率相似,且低剂量与不良事件减少相关。
研究设计与样本
- 多中心回顾性观察性队列研究,纳入2006年6月至2021年3月在三家机构诊断为非HIV PCP并接受TMP-SMX治疗的患者。
- 低剂量组55例(TMP<12.5 mg/kg/d),传统剂量组81例(TMP 12.5-20 mg/kg/d),采用倾向评分重叠加权法调整背景特征。
关键数值与推荐
- 低剂量定义:TMP<12.5 mg/kg/d;传统剂量定义:TMP 12.5-20 mg/kg/d。
- 低剂量组平均TMP-SMX剂量8.71 mg/kg/d,传统剂量组17.78 mg/kg/d。
- 总体队列平均年龄70.7岁,女性占55.1%。
临床怎么用
- 对于非HIV PCP患者,低剂量TMP-SMX可作为减少不良事件的治疗选择,且生存率与传统剂量相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trimethoprim-sulfamethoxazole (TMP-SMX) is an effective treatment for Pneumocystis jirovecii pneumonia (PCP) in immunocompromised patients with and without HIV infection; however, a high incidence of adverse events has been observed. Low-dose TMP-SMX is a potentially effective treatment with fewer adverse events; however, evidence is limited. RESEARCH QUESTION: What is the efficacy and safety of low-dose TMP-SMX for non-HIV PCP compared with conventional-dose TMP-SMX after adjusting for patient background characteristics? STUDY DESIGN AND METHODS: In this multicenter retrospective cohort study, we included patients diagnosed with non-HIV PCP and treated with TMP-SMX between June 2006 and March 2021 at three institutions. The patients were classified into low-dose (TMP < 12.5 mg/kg/d) and conventional-dose (TMP 12.5-20 mg/kg/d) groups. The primary end point was 30-day mortality, and the secondary end points were 180-day mortality, adverse events grade 3 or higher per the Common Terminology Criteria for Adverse Events v5.0, and initial treatment completion rates. Background characteristics were adjusted using the overlap weighting method with propensity scores. RESULTS: Fifty-five patients in the low-dose group and 81 in the conventional-dose group were evaluated. In the overall cohort, the average age was 70.7 years, and the proportion of women was 55.1%. The average dose of TMP-SMX was 8.71 mg/kg/d in the low-dose group and 17.78 mg/kg/d in the conventional-dose group. There was no significant difference in 30-day mortality (6.7% vs 18.4%, respectively; P = .080) or 180-day mortality (14.6% vs 26.1%, respectively; P = .141) after adjusting for patient background characteristics. The incidence of adverse events, especially nausea and hyponatremia, was significantly lower in the low-dose group (29.8% vs 59.0%, respectively; P = .005). The initial treatment completion rates were 43.3% and 29.6% in the low-dose and conventional-dose groups (P = .158), respectively. INTERPRETATION: Survival was similar between the low-dose and conventional-dose TMP-SMX groups, and low-dose TMP-SMX was associated with reduced adverse events in patients with non-HIV PCP.
引用
- Nagai T, Matsui H, Fujioka H, et al. Low-Dose vs Conventional-Dose Trimethoprim-Sulfamethoxazole Treatment for Pneumocystis Pneumonia in Patients Not Infected With HIV: A Multicenter, Retrospective Observational Cohort Study. Chest. 2023. PMID: 37574166. doi:10.1016/j.chest.2023.08.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。